BIOV.F Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 28.30 |
| 52 Week High | SEK 32.25 |
| 52 Week Low | SEK 22.40 |
| Beta | 0.22 |
| 11 Month Change | -4.07% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 7.81% |
| 5 Year Change | 71.52% |
| Change since IPO | 185.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOV.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.8% | 2.4% | 2.2% |
| 1Y | n/a | 16.2% | 31.7% |
Return vs Industry: Insufficient data to determine how BIOV.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BIOV.F performed against the US Market.
Price Volatility
| BIOV.F volatility | |
|---|---|
| BIOV.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOV.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BIOV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,814 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| BIOV.F fundamental statistics | |
|---|---|
| Market cap | US$9.02b |
| Earnings (TTM) | US$317.70m |
| Revenue (TTM) | US$2.30b |
28.4x
P/E Ratio3.9x
P/S RatioIs BIOV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV.F income statement (TTM) | |
|---|---|
| Revenue | SEK 25.44b |
| Cost of Revenue | SEK 5.44b |
| Gross Profit | SEK 19.99b |
| Other Expenses | SEK 16.48b |
| Earnings | SEK 3.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 10.23 |
| Gross Margin | 78.60% |
| Net Profit Margin | 13.82% |
| Debt/Equity Ratio | 47.1% |
How did BIOV.F perform over the long term?
See historical performance and comparison